Steven Nichtberger, MD

Co-Founder, Chairman and Chief Executive Officer, Cabaletta Bio

Steven Nichtberger, M.D., has over 25 years of healthcare industry experience focused on the development and commercialization of breakthrough medical advances. Most recently, he served as managing partner of GBF, LLC, providing advisory services to investors and leading academic scientists on commercialization of breakthrough advances, while also serving as founding Chairman of ControlRad, a privately-held medical technology company. He is an adjunct professor at the Wharton School and a Senior Fellow in the Vagelos Life Sciences & Management Program. From 2004 to 2011, Dr. Nichtberger was the founding CEO of Tengion, a company developing novel cell therapy based regenerative medicine products to treat urologic, oncologic and renal diseases. During his tenure, Tengion successfully developed research, clinical, manufacturing, regulatory and commercial capabilities to advance products from discovery to Phase 3-ready status. The company also raised $230 million, including through an IPO, from leading venture, public and strategic investors. Prior to that, Dr. Nichtberger served nine years in senior strategic and operating roles at Merck including global leadership of the human health marketing organization, P&L responsibility for a $3.5 billion portfolio of products, leadership roles relating to the formation and governance of the Merck-Schering Plough partnerships, and Merck commercial representation on Merck Research leadership and licensing teams. In 2008, while CEO of Tengion, Dr. Nichtberger was honored with the prestigious National Ernst and Young Entrepreneur of the Year Award in the Emerging Company Category while employees repeatedly rated Tengion among the top ten U.S. healthcare companies to work for in the annual Scientist magazine survey.

https://www.cabalettabio.com/